Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal irinotecan plus CAPOX for gastric cancer with peritoneal carcinomatosis
NL-OMON51789Phase 1Recruiting
- Sponsor
- Erasmus MC
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of irinotecan, capecitabine and oxaliplatin in gastric cancer (GC) and peritoneal carcinomatosis (PC), sponsored by Erasmus MC. Primary endpoint: Maximum tolerated dose and recommended phase II dose of intraperitoneal irinotecan. Started May 2022; status: recruiting.
02
Drugs
irinotecancapecitabineoxaliplatin
03
Conditions
gastric cancer (GC)peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NL-OMON51789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51789.